panTB-HM: a clinical trial of a pan-TB regimen targeting both host and microbe

  1. Don Mudzengi
  2. S Mashatole
  3. Q Xiang
  4. C Adrion
  5. N Glover
  6. T Ngwanto
  7. J Mdl
  8. S Boniface
  9. M Rassool
  10. L Paramo
  11. E Svensson
  12. A Fasanmi
  13. S Angelo
  14. M Moyo
  15. C Marx
  16. C Khosa
  17. N Mofokeng
  18. J Lalashowi
  19. C Nacy
  20. S Charalambous
  21. E Fumane
  22. V Maphossa
  23. T Beattie
  24. W Brumskine
  25. C Venter
  26. D Mapamba
  27. N Heinrich
  28. S Rajaram
  29. S Kooverjee
  30. M Nell
  31. A Easton
  32. S Foraida
  33. N Ntinginya
  34. Robert Wallis
0 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Background Newer oxazolidinones will be required to advance regimens in pan-TB indications. The addition of host-directed agents may help promote the recovery of lung function during TB treatment and prevent post-TB lung disease. Methods The panTB-HM trial assesses the capacity of regimens containing the oxazolidinone sutezolid and the anti-oxidant N-acetylcysteine to meet the target criteria proposed by WHO for pan-TB indications in a phase 2C trial. Discussion This trial is ground-breaking in its objectives and design for a pan-TB indication and its evaluation of lung function recovery. Trial registration The protocol was first registered on clinicaltrials.gov as NCT05686356 on 13 Jan 2023.

Related articles

Related articles are currently not available for this article.